⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15966191 | 0.86 | ALDH1A1 (0.32) | — | |
| Ether SCHEMBL9988157 | 0.84 | ALDH1A1 (0.31) | — | |
| SCHEMBL430949 | 0.83 | — | — | |
| SCHEMBL29059132 | 0.82 | ALDH1A1 (0.39) | — | |
| SCHEMBL10001697 | 0.80 | — | — | |
| SCHEMBL419805 | 0.80 | MEN1 (0.32) | — | |
| SCHEMBL1289421 | 0.80 | MEN1 (0.32) | — | |
| SCHEMBL13151054 | 0.79 | — | — | |
| SCHEMBL10158608 | 0.79 | HSD17B10 (0.35) | — | |
| SCHEMBL13732497 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 912 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630738-B1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2023-07-19 | — | — | EP | claimed |
| US-11352324-B2 | Methods | MEDIMMUNE LIMITED (GB) | 2022-06-07 | — | — | US | claimed |
| US-20200399215-A1 | METHODS | MEDIMMUNE LIMITED (GB) | 2020-12-24 | — | — | US | claimed |
| EP-3630738-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | Egis Gyógyszergyár Zrt. (HU) | 2020-04-08 | — | — | EP | claimed |
| US-20200087269-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | EGIS GYOGYSZERGYAR ZRT. (HU) | 2020-03-19 | — | — | US | claimed |
| WO-2018215807-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2018-11-29 | — | — | WO | claimed |
| EP-3323414-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | claimed |
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2508504-B1 | PROCESS FOR PREPARATION OF CYCLOALKANEDICARBOXYLIC ACID MONOESTERS | SUMITOMO CHEMICAL CO (JP) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-2508504-A1 | PROCESS FOR PREPARATION OF CYCLOALKANEDICARBOXYLIC ACID MONOESTERS | Sumitomo Chemical Co., Ltd (JP) | 2012-10-10 | — | — | EP | claimed |
| WO-2008068614-A2 | STEREOSELECTIVE SYNTHESIS OF 1-[6-ETHYL-1,2-DIHYDROXY-PROPYL)-PYRIDIN-3-YL]-3-[2-(4-METHYL-PIPERAZIN-1-YL)-BENZYL]-PYRROLIDIN-2-ONE | PFIZER PRODUCTS INC. (US) | 2008-06-12 | — | — | WO | claimed |
| EP-1594835-A4 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS INC (US) | 2007-05-02 | — | — | EP | claimed |
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | claimed |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | HONG BORCHERNG | 2006-08-03 | — | — | US | claimed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | claimed |
| EP-1594835-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | Auspex Pharmaceuticals, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | claimed |
| WO-2004064745-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-06-27 | — | — | US | disclosed |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | disclosed |
| EP-4387954-A1 | LONG-LIVED REDOX-ACTIVE MOLECULES WITH LOW REDOX POTENTIAL | President and Fellows of Harvard College (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11999757-B2 | Synthesis of boronate ester derivatives and uses thereof | MELINTA SUBSIDIARY CORP. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11998610-B2 | Conjugates and methods of using the same | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240173330-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER | REPARE THERAPEUTICS INC (CA) | 2024-05-30 | — | — | US | disclosed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | Revolution Medicines, Inc. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240156965-A1 | DICHALCOGENIDE PRODRUGS | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-05-16 | — | — | US | disclosed |
| US-11981703-B2 | Polynucleotide constructs | SIRIUS THERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240136561-A1 | ELECTRICAL REGENERATION OF ELECTROLYTES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-04-25 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4356736-A2 | SYNTHESIS OF BORONATE SALTS | Melinta Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-4355334-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER | Repare Therapeutics Inc. (CA) | 2024-04-24 | — | — | EP | disclosed |
| EP-4351662-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024074604-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | INSTITUTO BIOMAR, S.A (ES) | 2024-04-11 | — | — | WO | disclosed |
| EP-4349409-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | Instituto Biomar S.A. (ES) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024069592-A1 | N-(5-SUBSTITUTED-[(L,3,4-THIADIAZOLYL) OR (L,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE | REPARE THERAPEUTICS INC. (CA) | 2024-04-04 | — | — | WO | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| EP-4330426-A1 | METHODS OF TREATING CANCERS HAVING A BIALLELIC LOSS OF FUNCTION OR GENE OVEREXPRESSION MUTATION | Repare Therapeutics Inc. (CA) | 2024-03-06 | — | — | EP | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| EP-4320124-A1 | DICHALCOGENIDE PRODRUGS | Ludwig-Maximilians-Universität München (DE) | 2024-02-14 | — | — | EP | disclosed |
| EP-4319752-A1 | CARBOXAMIDE PYROLOPYRAZINE AND PYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF MYT1 AND USE THEREOF IN THE TREATMENT OF CANCER | Repare Therapeutics Inc. (CA) | 2024-02-14 | — | — | EP | disclosed |
| EP-4313156-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | Ludwig-Maximilians-Universität München (DE) | 2024-02-07 | — | — | EP | disclosed |
| EP-4101855-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| EP-3615544-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| EP-4292156-A1 | ELECTRICAL REGENERATION OF ELECTROLYTES | President and Fellows of Harvard College (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4289950-A2 | MACROCYCLIC COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND MEDICAL USES THEREOF | Revolution Medicines, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3604316-B1 | SYNTHESIS OF BORONATE SALTS | MELINTA THERAPEUTICS INC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230372491-A1 | ENDOSOMAL ESCAPE DOMAINS FOR DELIVERY OF MACROMOLECULES INTO CELLS | UNIV CALIFORNIA (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023220831-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-23 | — | — | WO | disclosed |
| US-11820775-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357253-A1 | AGONISTS OF STIMULATOR OF INTERFERON GENES STING | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230348456-A1 | QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | disclosed |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-11793895-B2 | Residualizing linkers and uses thereof | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION | 2023-10-24 | — | — | US | disclosed |
| US-11787813-B2 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors | KSQ Therapeutics, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230323344-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | ARES CAPITAL CORPORATION, AS AGENT | 2023-10-12 | — | — | US | disclosed |
| US-20230321083-A1 | Inhibitors of GPR174 and Uses Thereof | OMEROS CORP (US) | 2023-10-12 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| EP-4242304-A2 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | Warp Drive Bio, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230271954-A1 | COMPOUNDS USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230270895-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2023-08-31 | — | — | US | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230265071-A1 | ARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 | Plexium, Inc. | 2023-08-24 | — | — | US | disclosed |
| CN-116616633-A | Towel with self-cleaning function and preparation method | 厦门悠派新生活科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11724980-B2 | Quinones having high capacity retention for use as electrolytes in aqueous redox flow batteries | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-15 | — | — | US | disclosed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| US-20230242546-A1 | SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, AND 1,2,4-TRIAZINES AS TYK2 INHIBITORS | SUDO BIOSCIENCES LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242567-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | SIRIUS THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2023147421-A1 | ELECTROCHEMICAL CO2 CAPTURE WITH AIR STABLE REDOX SPECIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4101855-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-02 | — | — | EP | disclosed |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713325-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2023-08-01 | — | — | US | disclosed |
| EP-3630738-B1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2023-07-19 | — | — | EP | disclosed |
| EP-3247378-B1 | MACROCYCLIC COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND MEDICAL USES THEREOF | WARP DRIVE BIO INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230203046-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230158022-A1 | METHODS OF USING MYT1 INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2023-05-25 | — | — | US | disclosed |
| US-20230151014-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | REPARE THERAPEUTICS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230142913-A1 | TRICYCLIC HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-05-11 | — | — | US | disclosed |
| US-20230148184-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-2956437-B1 | ALBICIDIN DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | UNIV BERLIN TECH (DE) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023067132-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2023-04-27 | — | — | WO | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-20230122909-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | REPARE THERAPEUTICS INC. (CA) | 2023-04-20 | — | — | US | disclosed |
| WO-2023050007-A1 | N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA | REPARE THERAPEUTICS INC. (CA) | 2023-04-06 | — | — | WO | disclosed |
| EP-4159741-A1 | METHOD FOR PRODUCING A CHIMERIC POLYNUCLEOTIDE ENCODING A POLYPEPTIDE HAVING A TRIAZOLE-CONTAINING INTERNUCLEOTIDE LINKAGE | ModernaTX, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-3615544-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2023-03-22 | — | — | EP | disclosed |
| EP-4047002-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2023-03-08 | — | — | EP | disclosed |
| US-11597744-B2 | Chiral phosphoramidite auxiliaries and methods of their use | SIRIUS THERAPEUTICS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| WO-2023028041-A1 | ELECTROCHEMICAL REBALANCING METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023023303-A1 | LONG-LIVED REDOX-ACTIVE MOLECULES WITH LOW REDOX POTENTIAL | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20230052140-A1 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2023-02-16 | — | — | US | disclosed |
| US-20230051850-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-16 | — | — | US | disclosed |
| US-11578327-B2 | Oligonucleotide therapy for Wilson disease | DEEP GENOMICS INCORPORATED (CA) | 2023-02-14 | — | — | US | disclosed |
| EP-4126879-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | Repare Therapeutics Inc. (CA) | 2023-02-08 | — | — | EP | disclosed |
| EP-4125907-A1 | METHODS OF USING MYT1 INHIBITORS | Repare Therapeutics Inc. (CA) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023009719-A2 | STABILITY-ENHANCING COMPOSITIONS AND METHODS OF PREPARING COMPOUNDS | FOGHORN THERAPEUTICS INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
| US-11557786-B2 | Extending the lifetime of organic flow batteries via redox state management | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-17 | — | — | US | disclosed |
| EP-4112599-A1 | KEY INTERMEDIATE FOR SYNTHESIZING PROSTAGLANDIN COMPOUNDS AND PREPARATION METHOD THEREFOR | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022261777-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS FOR TREATING CANCER | REPARE THERAPEUTICS INC. (CA) | 2022-12-22 | — | — | WO | disclosed |
| EP-3870234-B1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022261467-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2022-12-15 | — | — | WO | disclosed |
| EP-4101855-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2022-12-14 | — | — | EP | disclosed |
| EP-4101930-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | ModernaTX, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-3271468-B1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION SL (ES) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022213204-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2022-10-13 | — | — | WO | disclosed |
| EP-4062942-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | Ludwig-Maximilians-Universität München (DE) | 2022-09-28 | — | — | EP | disclosed |
| US-20220296555-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20220281797-A1 | KEY INTERMEDIATE FOR SYNTHESIS OF PROSTAGLANDIN COMPOUND AND PREPARATION METHOD THEREOF | SHENZHEN CATALYS TECHNOLOGY CO., LTD (CN) | 2022-09-08 | — | — | US | disclosed |
| US-20220282246-A1 | OLIGONUCLEOTIDE THERAPY FOR STARGARDT DISEASE | DEEP GENOMICS INCORPORATED (CA) | 2022-09-08 | — | — | US | disclosed |
| US-20220275362-A1 | METHODS FOR TAGGING AND ENCODING OF PRE-EXISTING COMPOUND LIBRARIES | X-CHEM, INC. (US) | 2022-09-01 | — | — | US | disclosed |
| US-20220242883-A1 | Antitumoral Compounds | PHARMA MAR SA (ES) | 2022-08-04 | — | — | US | disclosed |
| US-20220228152-A1 | OLIGONUCLEOTIDE THERAPY FOR WOLMAN DISEASE AND CHOLESTERYL ESTER STORAGE DISEASE | DEEP GENOMICS INCORPORATED (CA) | 2022-07-21 | — | — | US | disclosed |
| EP-4025252-A1 | ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-4025253-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar S.A. (ES) | 2022-07-13 | — | — | EP | disclosed |
| EP-4023249-A1 | NUCLEIC ACID VACCINES | ModernaTX, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220193223-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| EP-4015005-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220185809-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2022-06-16 | — | — | US | disclosed |
| US-11352324-B2 | Methods | MEDIMMUNE LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-4003993-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | Repare Therapeutics Inc. (CA) | 2022-06-01 | — | — | EP | disclosed |
| EP-4004202-A1 | METHODS FOR TAGGING AND ENCODING OF PRE-EXISTING COMPOUND LIBRARIES | X-Chem, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220162173-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220162606-A1 | NRL EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE | NAYAN THERAPEUTICS, INC. | 2022-05-26 | — | — | US | disclosed |
| US-11339180-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2022-05-24 | — | — | US | disclosed |
| US-11332480-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2022-05-17 | — | — | US | disclosed |
| US-20220145292-A1 | LIGAND CLUSTERS AND METHODS OF THEIR USE AND PREPARATION | DEEP GENOMICS INCORPORATED (CA) | 2022-05-12 | — | — | US | disclosed |
| US-20220144849-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2022-05-12 | — | — | US | disclosed |
| US-20220143202-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WARP DRIVE BIO, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11325913-B2 | Compounds and methods for the treatment of malaria | THE BROAD INSTITUTE, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220133767-A1 | TARGETING MICRORNAS TO OVERCOME DRUG TOLERANCE AND RESISTANCE | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220110960-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20220098595-A1 | NR2E3 EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE | NAYAN THERAPEUTICS, INC. | 2022-03-31 | — | — | US | disclosed |
| US-20220088231-A1 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | OXFORD FINANCE LLC | 2022-03-24 | — | — | US | disclosed |
| EP-3169693-B1 | CHIMERIC POLYNUCLEOTIDES | MODERNATX INC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20220054664-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2022-02-24 | — | — | US | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | SENDA BIOSCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SENDA BIOSCIENCES INC (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3946390-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | President and Fellows of Harvard College (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2022026719-A2 | NRL ANTISENSE OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE | NAYAN THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-3931323-A1 | LIGAND CLUSTERS AND METHODS OF THEIR USE AND PREPARATION | Deep Genomics Incorporated (CA) | 2022-01-05 | — | — | EP | disclosed |
| US-20210405060-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | Revolution Medicines, Inc. | 2021-12-30 | — | — | US | disclosed |
| EP-3134131-B1 | NUCLEIC ACID VACCINES | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TOLLNINE, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210391591-A1 | EXTENDING THE LIFETIME OF ORGANIC FLOW BATTERIES VIA REDOX STATE MANAGEMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-12-16 | — | — | US | disclosed |
| US-11191854-B2 | Pharmacokinetic enhancements of bifunctional chelates and uses thereof | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2021-12-07 | — | — | US | disclosed |
| EP-3914713-A1 | NRL EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE | Nayan Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3914712-A1 | NR2E3 EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE | Nayan Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3682905-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3350333-B1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNATX INC (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3891122-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3890789-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2021-10-13 | — | — | EP | disclosed |
| EP-3890790-A1 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2021-10-13 | — | — | EP | disclosed |
| WO-2021195781-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE | REPARE THERAPEUTICS INC. (CA) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021195782-A1 | METHODS OF USING MYT1 INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-10-07 | — | — | WO | disclosed |
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
| US-20210290788-A1 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2021-09-23 | — | — | US | disclosed |
| US-20210290789-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2021-09-23 | — | — | US | disclosed |
| US-20210285955-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | WARP DRIVE BIO, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210283157-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SENDA BIOSCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210277002-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-09-09 | — | — | US | disclosed |
| EP-3873905-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING COMPOUNDS AND OF THEIR USE AS ATR KINASE INHIBITORS | Repare Therapeutics Inc. (CA) | 2021-09-08 | — | — | EP | disclosed |
| US-20210246146-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2021-08-12 | — | — | US | disclosed |
| EP-3861586-A2 | EXTENDING THE LIFETIME OF ORGANIC FLOW BATTERIES VIA REDOX STATE MANAGEMENT | President and Fellows of Harvard College (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210220467-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-11058698-B2 | Acylated active agents and methods of their use for the treatment of autoimmune disorders | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059830-B2 | Compounds that participate in cooperative binding and uses thereof | Revolution Medicines, Inc. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210206714-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210206771-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-07-08 | — | — | US | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3836971-A1 | CONJUGATES AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210177856-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-06-17 | — | — | US | disclosed |
| WO-2021119523-A1 | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021113635-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113620-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210162057-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-03 | — | — | US | disclosed |
| EP-3801489-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3801496-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3801512-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | President and Fellows of Harvard College (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3801587-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3536692-B1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3797097-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | President and Fellows of Harvard College (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20210085640-A1 | ACYLATED CATECHIN POLYPHENOLS AND METHODS OF THEIR USE FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-03-25 | — | — | US | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10948495-B2 | Methods and reagents for analyzing protein-protein interfaces | Revolution Medicines, Inc. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210070775-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2021-03-11 | — | — | US | disclosed |
| WO-2021043951-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2021-03-11 | — | — | WO | disclosed |
| WO-2021046260-A1 | ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES | ARCTURUS THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-20210061843-A1 | MULTIMERIC POLYNUCLEOTIDES AND USES THEREOF | MODERNATX, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20210060190-A1 | RESIDUALIZING LINKERS AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2021-03-04 | — | — | US | disclosed |
| WO-2021026395-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF THEIR USE IN REVERSING CANCER CHEMORESISTANCE | THE GENERAL HOSPITAL CORPORATION (US) | 2021-02-11 | — | — | WO | disclosed |
| US-20210032629-A1 | OLIGONUCLEOTIDE THERAPY FOR WILSON DISEASE | DEEP GENOMICS INCORPORATED (CA) | 2021-02-04 | — | — | US | disclosed |
| WO-2021022224-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF THEIR USE IN THE INHIBITION OF INTERACTION BETWEEN IL18 AND IL18R | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2021016525-A1 | METHODS FOR TAGGING AND ENCODING OF PRE-EXISTING COMPOUND LIBRARIES | X-CHEM, INC. (US) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021012049-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-01-28 | — | — | WO | disclosed |
| WO-2021007654-A1 | OLIGONUCLEOTIDE THERAPY FOR STARGARDT DISEASE | DEEP GENOMICS INCORPORATED (CA) | 2021-01-21 | — | — | WO | disclosed |
| US-20210009621-A1 | AMINOCOUMARIN COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-01-14 | — | — | US | disclosed |
| US-20210009497-A1 | QUINONES HAVING HIGH CAPACITY RETENTION FOR USE AS ELECTROLYTES IN AQUEOUS REDOX FLOW BATTERIES | NATIONAL SCIENCE FOUNDATION | 2021-01-14 | — | — | US | disclosed |
| EP-3759071-A1 | METHODS | MedImmune Limited (GB) | 2021-01-06 | — | — | EP | disclosed |
| EP-3757109-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Warp Drive Bio, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200399215-A1 | METHODS | MEDIMMUNE LIMITED (GB) | 2020-12-24 | — | — | US | disclosed |
| US-20200399276-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA | THE BROAD INSTITUTE, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| EP-3752614-A1 | OLIGONUCLEOTIDE THERAPY FOR WILSON DISEASE | Deep Genomics Incorporated (CA) | 2020-12-23 | — | — | EP | disclosed |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
| EP-3749632-A1 | QUINONES HAVING HIGH CAPACITY RETENTION FOR USE AS ELECTROLYTES IN AQUEOUS REDOX FLOW BATTERIES | President and Fellows of Harvard College (US) | 2020-12-16 | — | — | EP | disclosed |
| WO-2020237391-A1 | OLIGONUCLEOTIDE THERAPY FOR WOLMAN DISEASE AND CHOLESTERYL ESTER STORAGE DISEASE | DEEP GENOMICS INCORPORATED (CA) | 2020-12-03 | — | — | WO | disclosed |
| US-20200345725-A1 | Methods and Compositions for Treating Cancer | OMEROS CORPORATOIN | 2020-11-05 | — | — | US | disclosed |
| US-20200347074-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2020-11-05 | — | — | US | disclosed |
| EP-3091970-B1 | LXR AGONISTS AND USES THEREOF | RGENIX INC (US) | 2020-10-28 | — | — | EP | disclosed |
| WO-2020198275-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20200308197-A1 | SYNTHESIS OF BORONATE ESTER DERIVATIVES AND USES THEREOF | MELINTA SUBSIDIARY CORP. | 2020-10-01 | — | — | US | disclosed |
| US-10758636-B2 | Residualizing linkers and uses thereof | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2020-09-01 | — | — | US | disclosed |
| WO-2020154693-A1 | NRL EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE | NAYAN THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020154686-A1 | NR2E3 EXPRESSION REDUCING OLIGONUCLEOTIDES, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF THEIR USE | NAYAN THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| EP-3682905-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10709779-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200199102-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200188418-A1 | ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS | SENDA BIOSCIENCES, INC. | 2020-06-18 | — | — | US | disclosed |
| WO-2020118163-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020115556-A1 | RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020115548-A1 | RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY | Fusion Pharmaceuticals Inc. (CA) | 2020-06-11 | — | — | WO | disclosed |
| US-10669292-B2 | Synthesis of boronate salts and uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200140450-A1 | CHEMICAL METHOD OF PRODUCING SMTP GROUPS OR SMTP-7 AND INTERMEDIATES USED IN THE METHOD | SHOWA UNIVERSITY (JP) | 2020-05-07 | — | — | US | disclosed |
| US-20200140476-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | SIRIUS THERAPEUTICS, INC. | 2020-05-07 | — | — | US | disclosed |
| US-20200138812-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS LLC (US) | 2020-05-07 | — | — | US | disclosed |
| EP-3645546-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | Solstice Biologics, Ltd. (IE) | 2020-05-06 | — | — | EP | disclosed |
| EP-3638320-A2 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2020-04-22 | — | — | EP | disclosed |
| EP-3634430-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2020072406-A2 | EXTENDING THE LIFETIME OF ORGANIC FLOW BATTERIES VIA REDOX STATE MANAGEMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-3630738-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | Egis Gyógyszergyár Zrt. (HU) | 2020-04-08 | — | — | EP | disclosed |
| US-20200101030-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | KINTAI THERAPEUTICS, INC. | 2020-04-02 | — | — | US | disclosed |
| WO-2020006210-A9 | PYRIDOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TUFTS MEDICAL CENTER, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20200087269-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | EGIS GYOGYSZERGYAR ZRT. (HU) | 2020-03-19 | — | — | US | disclosed |
| EP-3619191-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2020-03-11 | — | — | EP | disclosed |
| EP-3492109-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2020-02-27 | — | — | US | disclosed |
| WO-2020037009-A1 | CONJUGATES AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| EP-3610022-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | Tollnine, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3606492-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3607326-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | Revolution Medicines, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3604316-A1 | SYNTHESIS OF BORONATE SALTS | Rempex Pharmaceuticals, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20200031851-A1 | SYNTHESIS OF BORONATE SALTS AND USES THEREOF | MELINTA SUBSIDIARY CORP. | 2020-01-30 | — | — | US | disclosed |
| US-10538535-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2020-01-21 | — | — | US | disclosed |
| US-10466249-B2 | Methods and reagents for analyzing protein-protein interfaces | Revolution Medicines, Inc. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-10442820-B2 | — | — | 2019-10-15 | — | — | US | disclosed |
| WO-2019157437-A9 | QUINONES HAVING HIGH CAPACITY RETENTION FOR USE AS ELECTROLYTES IN AQUEOUS REDOX FLOW BATTERIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-3536692-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| US-10407683-B2 | Circular polynucleotides | MODERNATX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3169335-B1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
| WO-2019161105-A1 | OLIGONUCLEOTIDE THERAPY FOR WILSON DISEASE | DEEP GENOMICS INCORPORATED (CA) | 2019-08-22 | — | — | WO | disclosed |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
| EP-2931319-B1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10385074-B2 | Synthesis of boronate salts and uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385088-B2 | Polynucleotide molecules and uses thereof | MODERNATX, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| WO-2019157437-A1 | QUINONES HAVING HIGH CAPACITY RETENTION FOR USE AS ELECTROLYTES IN AQUEOUS REDOX FLOW BATTERIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-08-15 | — | — | WO | disclosed |
| EP-3140310-B1 | SYNTHESIS OF BORONATE SALTS AND USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| WO-2019143910-A1 | MULTIMERIC POLYNUCLEOTIDES AND USES THEREOF | MODERNATX, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20190202855-A1 | POLYNUCLEOTIDE CONSTRUCTS | SIRIUS THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190194655-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE | BRADSHAW CURT W (US) | 2019-06-27 | — | — | US | disclosed |
| EP-3500581-A1 | POLYNUCLEOTIDE CONSTRUCTS | Solstice Biologics, Ltd. (IE) | 2019-06-26 | — | — | EP | disclosed |
| EP-3492109-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-10308595-B2 | Albicidin derivatives, their use and synthesis | Technische Universität Berlin (DE) | 2019-06-04 | — | — | US | disclosed |
| US-20190144503-A1 | METHODS FOR THE IDENTIFICATION OF BIFUNCTIONAL COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2019-05-16 | — | — | US | disclosed |
| US-10286086-B2 | Alternative nucleic acid molecules and uses thereof | MODERNATX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3173413-B1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3068443-B1 | RESIDUALIZING LINKERS AND USES THEREOF | CENTRE FOR PROBE DEV AND COMMERCIALIZATION (CA) | 2019-04-10 | — | — | EP | disclosed |
| US-20190083662-A1 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | OXFORD FINANCE LLC | 2019-03-21 | — | — | US | disclosed |
| US-20190078087-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | ARES CAPITAL CORPORATION, AS AGENT | 2019-03-14 | — | — | US | disclosed |
| US-10202389-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20190030194-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2019-01-31 | — | — | US | disclosed |
| US-20190015501-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190008948-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2019-01-10 | — | — | US | disclosed |
| US-20190000959-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| WO-2019006455-A1 | CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE | SOLSTICE BIOLOGICS, LTD. (IE) | 2019-01-03 | — | — | WO | disclosed |
| EP-2763701-B1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2018226732-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| WO-2018222975-A1 | METHODS FOR THE TREATMENT OF CANCER | RGENIX, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| US-20180346505-A1 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | SOLSTICE BIOLOGICS LTD (IE) | 2018-12-06 | — | — | US | disclosed |
| WO-2018215807-A1 | PROCESS FOR THE PRODUCTION OF OZANIMOD | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2018-11-29 | — | — | WO | disclosed |
| EP-3402477-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | The Rockefeller University (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2018204869-A1 | PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2018-11-08 | — | — | WO | disclosed |
| WO-2018204872-A2 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2018-11-08 | — | — | WO | disclosed |
| US-20180318434-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2018-11-08 | — | — | US | disclosed |
| US-20180312529-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2018-11-01 | — | — | US | disclosed |
| US-20180312536-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2018-11-01 | — | — | US | disclosed |
| US-20180303864-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-10-25 | — | — | US | disclosed |
| WO-2018189382-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | SOLSTICE BIOLOGICS, LTD. (IE) | 2018-10-18 | — | — | WO | disclosed |
| EP-3386517-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE | Solstice Biologics, Ltd. (IE) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018187401-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WARP DRIVE BIO, INC. (US) | 2018-10-11 | — | — | WO | disclosed |
| WO-2018187423-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | WARP DRIVE BIO, INC. (US) | 2018-10-11 | — | — | WO | disclosed |
| US-20180290983-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-10093741-B1 | IGF-1R monoclonal antibodies and uses thereof | Fusion Pharmaceuticals Inc. (CA) | 2018-10-09 | — | — | US | disclosed |
| US-10087205-B2 | Metal organic frameworks comprising a plurality of SBUS with different metal ions and/or a plurality of organic linking ligands with different functional groups | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180273544-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2018-09-27 | — | — | US | disclosed |
| WO-2018167270-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2018-09-20 | — | — | WO | disclosed |
| US-20180259535-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2018-09-13 | — | — | US | disclosed |
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-09-13 | — | — | US | disclosed |
| US-20180256750-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNA THERAPEUTICS, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-20180252726-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2018-09-06 | — | — | US | disclosed |
| US-10059711-B2 | Compounds and methods for the treatment of malaria | THE BROAD INSTITUTE, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-3355930-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | Warp Drive Bio, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10039839-B2 | Compounds that participate in cooperative binding and uses thereof | WARP DRIVE BIO, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180215753-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| EP-3350333-A2 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | ModernaTX, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-10022435-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023572-B2 | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180194736-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-06-14 | — | — | US | disclosed |
| US-9994563-B2 | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-06-12 | — | — | US | disclosed |
| US-9989535-B2 | Methods and reagents for analyzing protein-protein interfaces | WARP DRIVE BIO, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180148452-A1 | TOLL-LIKE RECEPTOR-7 AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148444-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-05-31 | — | — | US | disclosed |
| EP-3323414-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20180134695-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2018-05-17 | — | — | US | disclosed |
| US-20180117041-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-9950001-B2 | Polynucleotides having bioreversible groups | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180085391-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND CONDITIONS | MODERNA THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| EP-3288929-A1 | PHENOL DERIVATIVES TO TREAT CANCER | FUNDACIÓN MEDINA. Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía (ES) | 2018-03-07 | — | — | EP | disclosed |
| US-9908888-B2 | Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908867-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. | 2018-03-01 | — | — | US | disclosed |
| WO-2018035380-A1 | POLYNUCLEOTIDE CONSTRUCTS | SOLSTICE BIOLOGICS, LTD. (IE) | 2018-02-22 | — | — | WO | disclosed |
| US-9896444-B2 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-20180048011-A1 | HIGH pH ORGANIC FLOW BATTERY | U.S. DEPARTMENT OF ENERGY | 2018-02-15 | — | — | US | disclosed |
| US-9872900-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170369499-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9850214-B2 | Inhibitors of NEDD8-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850239-B2 | Pyrazolo[3,4-c]pyridine compounds and methods of use | GENENTECH, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170362605-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170342071-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL MYERS SQUIBB CO (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3247378-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Warp Drive Bio, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-3247377-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Warp Drive Bio, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9828372-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9827257-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2017-11-28 | — | — | US | disclosed |
| US-9828376-B2 | Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-9814718-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017187183-A1 | METHODS FOR THE IDENTIFICATION OF BIFUNCTIONAL COMPOUNDS | ITARA THERAPEUTICS (GB) | 2017-11-02 | — | — | WO | disclosed |
| US-9802927-B2 | Oxadiazine compounds and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9796725-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3229815-A2 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | Solstice Biologics, Ltd. (IE) | 2017-10-18 | — | — | EP | disclosed |
| US-20170279037-A1 | MAGNETIC MEMORY DEVICE AND NONVOLATILE MEMORY APPARATUS | KABUSHIKI KAISHA TOSHIBA (JP) | 2017-09-28 | — | — | US | disclosed |
| US-9772708-B2 | Display device with asymmetric masking layer | LG DISPLAY CO., LTD. (KR) | 2017-09-26 | — | — | US | disclosed |
| US-20170266185-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2017-09-21 | — | — | US | disclosed |
| US-20170260179-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2017-09-14 | — | — | US | disclosed |
| US-20170260179-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2017-09-14 | — | — | US | disclosed |
| US-9750709-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-09-05 | — | — | US | disclosed |
| US-9750759-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2017-09-05 | — | — | US | disclosed |
| US-9750842-B2 | Polymeric adhesive for anchoring compliant materials to another surface | HYALEX ORTHOPAEDICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170250152-A1 | Chip embedding package with solderable electric contact | INFINEON TECHNOLOGIES AG (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170245443-A1 | Disposable diaper recycling and applications thereof | ZYNNOVATION LLC (US) | 2017-08-31 | — | — | US | disclosed |
| EP-2964222-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9738638-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738638-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738890-B2 | Cloning method | DSM IP ASSETS B.V. (NL) | 2017-08-22 | — | — | US | disclosed |
| US-20170217968-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9717618-B2 | Gastrointestinal device with associated commensal microbes | ELWHA LLC (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170204422-A1 | CIRCULAR POLYNUCLEOTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170202979-A1 | TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES | MODERNATX, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2017123568-A2 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| US-9707116-B2 | Gastrointestinal device with associated microbe-promoting agents | ELWHA LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707232-B2 | Liver X receptor modulators | VITAE PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9703409-B2 | Liquid crystal display device | PANASONIC LIQUID CRYSTAL DISPLAY CO., LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| US-20170192580-A1 | Display Device with Detoured Signal Line | LG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
| US-9698022-B2 | Self-aligned floating gate in a vertical memory structure | INTEL CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170185191-A1 | Display Device with Light Shield | LG DISPLAY CO., LTD. (KR) | 2017-06-29 | — | — | US | disclosed |
| US-9691684-B2 | Integrated circuit device including through-silicon via structure and decoupling capacitor and method of manufacturing the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-06-27 | — | — | US | disclosed |
| US-20170176797-A1 | Display Device with Capping Layer | LG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
| US-20170177125-A1 | Display Device with Asymmetric Masking Layer | LG DISPLAY CO., LTD. (KR) | 2017-06-22 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170179126-A1 | INTEGRATED CIRCUIT HAVING CHEMICALLY MODIFIED SPACER SURFACE | TEXAS INSTRUMENTS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-9685453-B2 | Method of manufacturing a nonvolatile memory cell and a field effect transistor | RENESAS ELECTRONICS CORPORATION (JP) | 2017-06-20 | — | — | US | disclosed |
| WO-2017100461-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE | SOLSTICE BIOLOGICS, LTD. (IE) | 2017-06-15 | — | — | WO | disclosed |
| WO-2016144909-A9 | HIGH pH ORGANIC FLOW BATTERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | WO | disclosed |
| EP-3177732-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND CONDITIONS | ModernaTX, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2763535-B1 | AZAINDOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9669031-B2 | MNK inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3173413-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9663525-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| US-20170101398-A1 | PYRAZOLYL SUBSTITUTED TETRAHYDROPYRANYLSULFONES | Grünenthal GmbH (DE) | 2017-04-13 | — | — | US | disclosed |
| US-20170101429-A1 | METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-04-13 | — | — | US | disclosed |
| EP-3152308-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | Solstice Biologics, Ltd. (IE) | 2017-04-12 | — | — | EP | disclosed |
| US-20170097359-A1 | METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2017-04-06 | — | — | US | disclosed |
| US-20170095565-A1 | CHEMICALLY MODIFIED SMALL MOLECULES | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | disclosed |
| WO-2017049286-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049275-A2 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017044877-A1 | PHENETHYLDIHYDROBENZODIOXOLONES AND METHODS OF USE | SEQUOIA SCIENCES, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20170066753-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-03-09 | — | — | US | disclosed |
| EP-3137447-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Rgenix, Inc. (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20170058334-A1 | REACTION VESSEL FOR CARRYING OUT ARRAY PROCESSES | CLONDIAG CHIP TECHNOLOGIES GMBH (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170058334-A1 | REACTION VESSEL FOR CARRYING OUT ARRAY PROCESSES | CLONDIAG CHIP TECHNOLOGIES GMBH (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057961-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170057979-A1 | SYNTHESIS OF BORONATE SALTS AND USES THEREOF | MELINTA SUBSIDIARY CORP. | 2017-03-02 | — | — | US | disclosed |
| US-9579300-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof | NANOPHARMACEUTICALS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20170007603-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2017-01-12 | — | — | US | disclosed |
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-05 | — | — | US | disclosed |
| US-9527839-B2 | Benzimidazole tetrahydropyran derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160368923-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-22 | — | — | US | disclosed |
| EP-2861565-B1 | Syringolin and glidobactin analogs as proteasome inhibitors for the treatment of cancer | UNIV CALIFORNIA (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160331913-A1 | METHODS AND APPARATUS FOR PRODUCING HERBAL VAPOR | CANNAKORP, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160331828-A1 | NUCLEIC ACID VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| EP-3091970-A1 | LXR AGONISTS AND USES THEREOF | Rgenix, Inc. (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-3091006-A1 | SULFONYLATION PROCESS USING NONAFLUOROBUTANESULFONYL FLUORIDE | Janssen Pharmaceutica N.V. (BE) | 2016-11-09 | — | — | EP | disclosed |
| US-20160317647-A1 | NUCLEIC ACID VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160317536-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-11-03 | — | — | US | disclosed |
| WO-2016176636-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20160317493-A1 | Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | disclosed |
| WO-2016174226-A1 | PHENOL DERIVATIVES TO TREAT CANCER | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2016-11-03 | — | — | WO | disclosed |
| EP-3088396-A1 | PHENOL DERIVATIVES TO TREAT CANCER | FUNDACIÓN MEDINA. Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía (ES) | 2016-11-02 | — | — | EP | disclosed |
| US-20160311807-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3086202-A1 | THERMAL INTERFACE | ALCATEL LUCENT (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-9475807-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475807-B2 | 2-(1H-indazol-3-yl)-1H-imidazo[4,5-C]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160303208-A1 | METHOD FOR TREATING AMYLOID DISEASE | NEW YORK UNIVERSITY (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3081569-A1 | IMIDAZOLE DERIVATIVE USED AS ANTIVIRAL AGENT AND USE THEREOF IN PREPARATION OF MEDICAMENT | Medshine Discovery Inc. (CN) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080289-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9469608-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160297812-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2016-10-13 | — | — | US | disclosed |
| US-20160297812-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2016-10-13 | — | — | US | disclosed |
| US-20160289235-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA | THE BROAD INSTITUTE, INC. (US) | 2016-10-06 | — | — | US | disclosed |
| EP-2739629-B1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENT MANAGEMENT (AU) | 2016-10-05 | — | — | EP | disclosed |
| US-9458082-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160279272-A1 | RESIDUALIZING LINKERS AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2016-09-29 | — | — | US | disclosed |
| US-9453018-B2 | Pyrimidinones as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452167-B2 | Heterocyclic compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-09-27 | — | — | US | disclosed |
| EP-3068443-A2 | RESIDUALIZING LINKERS AND USES THEREOF | Centre for Probe Development and Commercialization (CA) | 2016-09-21 | — | — | EP | disclosed |
| EP-3068387-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA | The Broad Institute, Inc. (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-2882744-B1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-21 | — | — | EP | disclosed |
| US-20160268437-A1 | SEMICONDUCTOR DEVICE AND METHOD FOR MANUFACTURING THE SAME | SEMICONDUCTOR ENERGY LAB (JP) | 2016-09-15 | — | — | US | disclosed |
| WO-2016145099-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO FLT3 PROTEINS | AGENSYS, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016144909-A1 | HIGH pH ORGANIC FLOW BATTERY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160265131-A1 | NICKEL AND/OR CHROMIUM PLATED MEMBER AND METHOD FOR MANUFACTURING THE SAME | JIAXING MINHUI AUTOMOTIVE PARTS CO., LTD. (CN) | 2016-09-15 | — | — | US | disclosed |
| EP-2825542-B1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-3066105-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | Solstice Biologics, Ltd. (IE) | 2016-09-14 | — | — | EP | disclosed |
| US-20160257961-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | BRADSHAW CURT W (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257687-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2016-09-08 | — | — | US | disclosed |
| US-20160257687-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2016-09-08 | — | — | US | disclosed |
| EP-2635602-B1 | ANTI C-MET ANTIBODIES | ARGEN X NV (NL) | 2016-09-07 | — | — | EP | disclosed |
| US-9428507-B2 | Compounds for the treatment of malaria | THE BROAD INSTITUTE, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428524-B2 | Synthetic process for the manufacture of ecteinascidin compounds | PHARMA MAR, S.A. (ES) | 2016-08-30 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160244455-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-9422225-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160237108-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-18 | — | — | US | disclosed |
| US-9416135-B2 | Liver X receptor modulators | VITAE PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| EP-3052511-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-3052479-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-3053585-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| US-9399627-B2 | Substituted macrocyclic compounds having proteasome inhibitory activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-26 | — | — | US | disclosed |
| US-9397194-B2 | Method for manufacturing semiconductor device with oxide semiconductor ohmic conatct layers | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-07-19 | — | — | US | disclosed |
| WO-2016112295-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WARP DRIVE BIO, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-20160200705-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2016-07-14 | — | — | US | disclosed |
| WO-2016112279-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WARP DRIVE BIO, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-20160199506-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2016-07-14 | — | — | US | disclosed |
| US-20160194368-A1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194625-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNATX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160185717-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2016-06-30 | — | — | US | disclosed |
| WO-2016094677-A2 | MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP | SOLSTICE BIOLOGICS, LTD. (IE) | 2016-06-16 | — | — | WO | disclosed |
| US-20160159797-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359377-B2 | Substituted imidazo[1,2-a]imidazo[4′,5′:4,5]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2016-06-07 | — | — | US | disclosed |
| US-9359381-B2 | Tricyclic compounds for inhibiting the CFTR channel | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| US-20160152617-A1 | COMPOUNDS FOR THE TREATMENT OF MALARIA | THE BROAD INSTITUTE, INC. | 2016-06-02 | — | — | US | disclosed |
| EP-2195370-B1 | METHOD OF MAKING A SHEET OF BUILDING MATERIAL | G R GREEN BUILDING PRODUCTS INC (CA) | 2016-05-25 | — | — | EP | disclosed |
| EP-2918275-B1 | Alternative nucleic acid molecules and uses thereof | MODERNA THERAPEUTICS INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9340537-B2 | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVATIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| WO-2016066818-A1 | COMPOSITIONS AND PEPTIDES HAVING DUAL GLP-1R AND GLP-2R AGONIST ACTIVITY | GUBRA APS (DK) | 2016-05-06 | — | — | WO | disclosed |
| EP-2597091-B1 | Antitumoral Compounds | PHARMA MAR SA (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-9315483-B2 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2508504-B1 | PROCESS FOR PREPARATION OF CYCLOALKANEDICARBOXYLIC ACID MONOESTERS | SUMITOMO CHEMICAL CO (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9310291-B2 | Reaction vessel for carrying out array processes | CLONDIAG CHIP TECHNOLOGIES GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9310291-B2 | Reaction vessel for carrying out array processes | CLONDIAG CHIP TECHNOLOGIES GMBH (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20160096839-A1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-07 | — | — | US | disclosed |
| US-20160090380-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-31 | — | — | US | disclosed |
| US-20160090380-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-31 | — | — | US | disclosed |
| US-9295719-B2 | Method for treating amyloid disease | NEW YORK UNIVERSITY (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160085003-A1 | MATERIALS, COMPONENTS, AND METHODS FOR USE WITH EXTREME ULTRAVIOLET RADIATION IN LITHOGRAPHY AND OTHER APPLICATIONS | JAISWAL SUPRIYA (US) | 2016-03-24 | — | — | US | disclosed |
| EP-2998288-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals, Inc. (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2635603-B1 | C-MET ANTIBODY COMBINATIONS | ARGEN X NV (NL) | 2016-03-23 | — | — | EP | disclosed |
| US-9289395-B2 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof | NANOPHARMACEUTICALS LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290500-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160075701-A1 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2016-03-17 | — | — | US | disclosed |
| EP-2348857-B1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| US-9269817-B2 | Semiconductor device and manufacturing method thereof, delamination method, and transferring method | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9263248-B2 | Pseudo-substrate for use in the production of semiconductor components and method for producing a pseudo-substrate | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2016-02-16 | — | — | US | disclosed |
| WO-2016022914-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND CONDITIONS | MODERNA THERAPEUTICS, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| EP-2200997-B9 | Synthesis of deuterated benzodioxoles | CONCERT PHARMACEUTICALS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Technische Universität Berlin (DE) | 2015-12-31 | — | — | US | disclosed |
| EP-2956437-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Centre de Cooperation Internationale en Recherche Agronomique pour le Developpement (FR) | 2015-12-23 | — | — | EP | disclosed |
| WO-2015195179-A2 | METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196118-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196128-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015188197-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-12-10 | — | — | WO | disclosed |
| US-20150344454-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2015-12-03 | — | — | US | disclosed |
| US-20150342972-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2015-12-03 | — | — | US | disclosed |
| US-9199991-B2 | Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199991-B2 | Indazole inhibitors of the WNT signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150336986-A1 | TRICYCLIC COMPOUNDS FOR INHIBITING THE CFTR CHANNEL | NOVARTIS AG (CH) | 2015-11-26 | — | — | US | disclosed |
| US-20150336963-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2015-11-26 | — | — | US | disclosed |
| EP-2944637-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM Corporation (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-9187445-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2015-11-17 | — | — | US | disclosed |
| US-9184274-B2 | Semiconductor apparatus and manufacturing method of the semiconductor apparatus | SONY CORPORATION (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150315141-A1 | Thrombin Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2015168465-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20150311062-A1 | METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE AND METHOD OF MAINTAINING DEPOSITION APPARATUS | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-10-29 | — | — | US | disclosed |
| US-20150303280-A1 | SEMICONDUCTOR DEVICE AND METHOD FOR MANUFACTURING THE SAME | SEMICONDUCTOR ENERGY LAB (JP) | 2015-10-22 | — | — | US | disclosed |
| WO-2015161037-A1 | VERY LOW DENSITY METAL ORGANIC FRAMEWORKS WITH LARGE PORE VOLUMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| US-9166373-B1 | Laser devices having a gallium and nitrogen containing semipolar surface orientation | Soraa Laser Diode, Inc. (US) | 2015-10-20 | — | — | US | disclosed |
| WO-2015157239-A1 | FUNCTIONALIZED AND MULTIVARIATE BTB-BASED METAL ORGANIC FRAMEWORKS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-15 | — | — | WO | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2918275-A1 | Alternative nucleic acid molecules and uses thereof | Roy, Atanu (US) | 2015-09-16 | — | — | EP | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9134330-B2 | Detection method | TEIKYO UNIVERSITY (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20150252048-A1 | SUBSTITUTED N-(3-PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH | 2015-09-10 | — | — | US | disclosed |
| US-20150250787-A1 | COMPOUNDS FOR USE IN TREATING SKIN CANCERS | VITAE PHARMACEUTICALS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150252322-A1 | Methods, Apparatus, and Systems for Fabrication of Polymeric Nano-and Micro-Fibers in Aligned Configurations | CARNEGIE MELLON UNIVERSITY | 2015-09-10 | — | — | US | disclosed |
| US-20150238516-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| WO-2015116886-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| WO-2015116882-A1 | MACROCYCLIC FACTOR XIA INHIBITORS CONDENSED WITH HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150210575-A1 | BIOLOGICAL TREATMENT SYSTEMS UTILIZING SELECTIVELY PERMEABLE BARRIERS | CAMBRIAN INNOVATION INC. (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150196566-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197516-A1 | NOVEL BENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | Merck Sharp & Dohme Corp. a corporation, a subsidiary of Merck & Co., Inc. | 2015-07-16 | — | — | US | disclosed |
| WO-2015106164-A1 | LXR AGONISTS AND USES THEREOF | RGENIX, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-9082857-B2 | Semiconductor device comprising an oxide semiconductor layer | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-1954669-B1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-9073931-B2 | Liver X receptor modulators | VITAE PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2015089481-A2 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015089479-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015089511-A2 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150165005-A1 | Method for Treating Amyloid Disease | NEW YORK UNIVERSITY (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150152105-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-06-04 | — | — | US | disclosed |
| US-20150152105-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2015-06-04 | — | — | US | disclosed |
| US-9045463-B2 | Phenyl ethynyl derivatives as hepatitis C virus inhibitors | JANSSEN R&D IRELAND (IE) | 2015-06-02 | — | — | US | disclosed |
| US-20150141392-A1 | SUBSTITUTED MACROCYCLIC COMPOUNDS HAVING PROTEASOME INHIBITORY ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-05-21 | — | — | US | disclosed |
| WO-2015073575-A2 | RESIDUALIZING LINKERS AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2015-05-21 | — | — | WO | disclosed |
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| WO-2015069932-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015070204-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA | THE BROAD INSTITUTE, INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| US-9029352-B2 | Process for the preparation of C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-12 | — | — | US | disclosed |
| US-20150126485-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-23 | — | — | US | disclosed |
| EP-2648192-B1 | WATER BLOCKING ELECTRIC CABLE | J POWER SYSTEMS CORP (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2861565-A2 | SUBSTITUTED MACROCYCLIC COMPOUNDS HAVING PROTEASOME INHIBITORY ACTIVITY | The Regents of The University of California (US) | 2015-04-22 | — | — | EP | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015051169-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| US-9000161-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000161-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-8993582-B2 | Processes for preparing JAK inhibitors and related intermediate compounds | INCYTE CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-8987298-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987298-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150065515-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS, LLC | 2015-03-05 | — | — | US | disclosed |
| US-8971368-B1 | Laser devices having a gallium and nitrogen containing semipolar surface orientation | Soraa Laser Diode, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| EP-2576569-B1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS AND INTERMEDIATES | PHARMA MAR SA (ES) | 2015-01-14 | — | — | EP | disclosed |
| US-20150011572-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| WO-2015000825-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015002755-A2 | COMPOUNDS FOR THE TREATMENT OF MALARIA | THE BROAD INSTITUTE, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| EP-2821394-A1 | Compounds with antibacterial activity | Fundacion MEDINA. Centro de Excelencia en Investigacion de Medicamentos Innovadores en Andalucia (ES) | 2015-01-07 | — | — | EP | disclosed |
| EP-2814791-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140364395-A1 | Pyranyl Aryl Methyl Benzoquinolinone M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364423-A1 | Pyrazinopyrazines and Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
| US-20140343086-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-20140336387-A1 | SYNTHESIS OF DEUTERATED CATECHOLS AND BENZO[D][1,3]DIOXOLES AND DERIVATIVES THEREOF | CONCERT PHARMACEUTICALS, INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140314665-A1 | NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS THEREOF | NANOPHARMACEUTICALS LLC (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2014170295-A1 | COMPOUNDS POTENTIATING THE ACTIVITY OF ANTIFUNGAL DRUGS | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2014-10-23 | — | — | WO | disclosed |
| EP-2792683-A1 | Compounds potentiating the activity of antifungal drugs | Fundacion MEDINA. Centro de Excelencia en Investigacion de Medicamentos Innovadores en Andalucia (ES) | 2014-10-22 | — | — | EP | disclosed |
| EP-2340243-B1 | HETEROARYL SUBSTITUTED INDOLE COMPOUNDS USEFUL AS MMP-13 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-20140296339-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2014-10-02 | — | — | US | disclosed |
| US-8847249-B2 | Solid-state optical device having enhanced indium content in active regions | SORAA, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846664-B2 | Pyrazinopyrazines and derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846702-B2 | Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8841278-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| WO-2014143799-A2 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-8835535-B2 | Aqueous dispersions of silica for increasing early strength in cementitious preparations | EVONIK DEGUSSA GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-8829195-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8822498-B2 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822430-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-02 | — | — | US | disclosed |
| WO-2014125075-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Technische Universität Berlin (DE) | 2014-08-21 | — | — | WO | disclosed |
| US-8809356-B2 | Inhibitors of NEDD8-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| EP-2210665-B1 | Apparatus for detecting target molecules | CLONDIAG GMBH (DE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2748168-A2 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20140179696-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179696-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20140171417-A1 | TRICYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| EP-2739629-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | Biota Scientific Management Pty Ltd (AU) | 2014-06-11 | — | — | EP | disclosed |
| US-8748388-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-06-10 | — | — | US | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| EP-2323638-B1 | COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | HILLS PET NUTRITION INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8715449-B2 | Process for forming an insulated container having artwork | BERRY PLASTICS CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| US-8710264-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-04-29 | — | — | US | disclosed |
| US-20140113906-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2014-04-24 | — | — | US | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
| US-20140088096-A9 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8673936-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673936-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-03-18 | — | — | US | disclosed |
| US-8669234-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8664241-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664241-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-20140051656-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140046072-A1 | PROCESS FOR THE PREPARATION OF HETEROCYCLIC ESTER DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045789-A1 | PROCESS FOR THE PREPARATION OF C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-13 | — | — | US | disclosed |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2013188750-A2 | SUBSTITUTED MACROCYCLIC COMPOUNDS HAVING PROTEASOME INHIBITORY ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-12-19 | — | — | WO | disclosed |
| US-20130310395-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| US-8586020-B2 | Poly(organophosphazene) composition for biomaterials | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-11-19 | — | — | US | disclosed |
| EP-2200997-B1 | Synthesis of deuterated benzodioxoles | CONCERT PHARMACEUTICALS INC (US) | 2013-11-06 | — | — | EP | disclosed |
| EP-2231633-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-10-30 | — | — | EP | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130263961-A1 | COMPOSITE PIPE HAVING IMPROVED BONDING STRENGTH BETWEEN HETEROGENEOUS MATERIALS, AND APPARATUS AND METHOD OF MANUFACTURING THE SAME | LORDO AMERICA, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130253193-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253190-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253190-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130217682-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| WO-2013123169-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20130203176-A1 | DETECTION METHOD | TEIKYO UNIVERSITY (JP) | 2013-08-08 | — | — | US | disclosed |
| WO-2013115912-A1 | PROCESS FOR THE PRODUCTION OF POLYMERIC COMPOSITIONS USEFUL AS OIL MODIFIERS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-8501968-B2 | Antitumoral dihydropyran-2-one compounds | PHARMAMAR, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| US-8487094-B2 | Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8481556-B2 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Merck, Sharp & Dohms, Corp. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8470611-B2 | Biologically self-assembled nanotubes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2013020164-A9 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-06-20 | — | — | WO | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150388-A1 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| EP-2597091-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2013-05-29 | — | — | EP | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| US-8415346-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20130083588-A1 | MEMORY ELEMENT AND SIGNAL PROCESSING CIRCUIT | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8410284-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410284-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | PHARMA MAR, S.A. (ES) | 2013-03-14 | — | — | US | disclosed |
| WO-2013028832-A2 | INHIBITORS OF NEDD8-ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | WO | disclosed |
| US-20130039906-A1 | PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | US | disclosed |
| WO-2013020164-A1 | COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-02-14 | — | — | WO | disclosed |
| EP-2231695-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-02-13 | — | — | EP | disclosed |
| US-20130012540-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-10 | — | — | US | disclosed |
| US-8329897-B2 | Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8324406-B2 | Antitumoral dihydropyran-2-one compounds | PHARMA MAR, S.A. (ES) | 2012-12-04 | — | — | US | disclosed |
| US-8314071-B2 | Bioactive molecules from co-cultivation of microbes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2012-11-15 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| EP-2508504-A1 | PROCESS FOR PREPARATION OF CYCLOALKANEDICARBOXYLIC ACID MONOESTERS | Sumitomo Chemical Co., Ltd (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-8283358-B2 | N-sulfonamido polycyclic pyrazolyl compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| EP-2231590-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2012-08-15 | — | — | EP | disclosed |
| US-8242280-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120190870-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | MARTIN LOPEZ MA JESUS (ES) | 2012-07-26 | — | — | US | disclosed |
| US-20120157438-A1 | PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME CORP (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20120136027-A1 | Phenyl Ethynyl Derivatives As Hepatitis C Virus Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2012-05-31 | — | — | US | disclosed |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2183229-B1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2012-04-18 | — | — | EP | disclosed |
| US-8138197-B2 | Spirochromanon derivatives | MSD K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8138226-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2231590-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2012-03-14 | — | — | EP | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| EP-2032551-B9 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR SA (ES) | 2012-02-29 | — | — | EP | disclosed |
| US-20120041063-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2012-02-16 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
| EP-2404912-A2 | Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds | Pharma Mar S.A. (ES) | 2012-01-11 | — | — | EP | disclosed |
| EP-2404913-A2 | Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds | Pharma Mar S.A. (ES) | 2012-01-11 | — | — | EP | disclosed |
| EP-2403524-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | Agensys, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8088368-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110288078-A1 | PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110281910-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-17 | — | — | US | disclosed |
| WO-2011134067-A1 | NOVEL AMINO ACID MOLECULE AND USES THEREOF | 6570763 CANADA INC. (CA) | 2011-11-03 | — | — | WO | disclosed |
| US-20110269957-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-8026257-B2 | Substituted heterocyclic ethers and their use in CNS disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026257-B2 | Substituted heterocyclic ethers and their use in CNS disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026383-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives | BASF SE (DE) | 2011-09-27 | — | — | US | disclosed |
| EP-2032551-B1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR SA (ES) | 2011-08-31 | — | — | EP | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-08-25 | — | — | US | disclosed |
| US-7964728-B2 | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-06-21 | — | — | US | disclosed |
| US-7964728-B2 | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-06-21 | — | — | US | disclosed |
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110130424-A1 | SUBSTITUTED PHENYLPIPERIDINES WITH SEROTONINERGIC ACTIVITY AND ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130393-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-06-02 | — | — | US | disclosed |
| EP-2323994-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| US-20110118473-A1 | PROCESS FOR CONVERTING 9-DIHYDRO-13ACETYLBACCATIN III PACLITAXEL AND DOCETAXEL | 6570763 CANADA INC. (CA) | 2011-05-19 | — | — | US | disclosed |
| US-20110118136-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOESTER HUBERT | 2011-05-19 | — | — | US | disclosed |
| US-7935688-B2 | Vitamin D-like compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| EP-2081893-B1 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS INC (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110060146-A1 | VITAMIN-D-LIKE COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-10 | — | — | US | disclosed |
| US-20110046411-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES | CIBA SPECIALTY CHEMICALS CORPORATION | 2011-02-24 | — | — | US | disclosed |
| US-20110034549-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2011-02-10 | — | — | US | disclosed |
| US-7879829-B2 | 1,2-Dihydrofuran-25-Hydroxy-19-nor Vitamin D3 used for the treatment or prophylaxis of autoimmune diseases, some types of cancers, secondary hyperthyroidism, psoriasis, or other skin diseases | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-7858560-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-7855302-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino-3.5-dihydroxyhepanoic acid derivatives and intermediates thereof | CIBA SPECIALTY CHEMICALS CORP. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20100310512-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2010-12-09 | — | — | US | disclosed |
| US-7847111-B2 | Semi-synthetic route for the preparation of paclitaxel, docetaxel, and 10-deacetylbaccatin III from 9-dihydro-13-acetylbaccatin III | CANADA INC. (CA) | 2010-12-07 | — | — | US | disclosed |
| US-20100298168-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| EP-1583972-B1 | METHODS FOR IDENTIFYING DRUG NON-TARGET PROTEINS | CAPROTEC BIOANALYTICS GMBH (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20100292163-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-18 | — | — | US | disclosed |
| US-20100280108-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-04 | — | — | US | disclosed |
| US-20100256363-A1 | SYNTHESIS OF INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| WO-2010111018-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 24P4C12 PROTEINS | AGENSYS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249051-A1 | Bioactive Molecules from Co-Cultivation of Microbes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100248264-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | HK PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7803831-B2 | 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20100222257-A1 | SUBSTITUTED PHENETHYLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-7767860-B2 | Substituted amino alcohols | AUSPEX PHARMACEUTICALS, INC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7745665-B2 | Substituted phenethylamines | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100137244-A1 | PREPARATION AND UTILITY OF HMG-COA REDUCTASE INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2183234-A1 | PROCESS FOR CONVERTING 9-DIHYDRO-13-ACETYLBACCATIN III INTO DOCETAXEL OR PACLITAXEL | 6570763 Canada Inc. (CA) | 2010-05-12 | — | — | EP | disclosed |
| US-7691904-B2 | pH sensitive prodrugs of 2,6-diisopropylphenol | AUSPEX PHARMACEUTICALS, INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-7692034-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-04-06 | — | — | US | disclosed |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. | 2010-04-01 | — | — | US | disclosed |
| EP-2161250-A1 | Process for the preparatiom of 7-amino-syn-3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2010-03-10 | — | — | EP | disclosed |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| EP-1404642-B1 | Process for the preparatiom of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2010010150-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-28 | — | — | WO | disclosed |
| US-7648974-B1 | 19-nor-vitamin D analogs with 3,2-dihydrofuran ring | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-01-19 | — | — | US | disclosed |
| US-20100009950-A1 | SUBSTITUTED ETHANOLAMINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009944-A1 | 19-Nor-Vitamin D Analogs with 1,2-Dihydrofuran Ring | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2010-01-14 | — | — | US | disclosed |
| US-20100009945-A1 | 19-NOR-VITAMIN D ANALOGS WITH 3,2-DIHYDROFURAN RING | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2010-01-14 | — | — | US | disclosed |
| US-20090312435-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC (US) | 2009-12-17 | — | — | US | disclosed |
| US-7626021-B2 | Fused ring heterocycle kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| US-7598273-B2 | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090247628-A1 | SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7589239-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090215831-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090209592-A1 | INHIBITORS OF THE GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-7572816-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-23 | — | — | US | disclosed |
| US-20090182057-A1 | DEUTERATED AMINOGLYCIDAL COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7550607-B2 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | AUSPEX PHARMACEUTICAL, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| WO-2009075890-A2 | METHOD FOR SYNTHESIS OF TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090143432-A1 | Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090137609-A1 | VITAMIN D-LIKE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7531695-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICAL, INC (US) | 2009-05-12 | — | — | US | disclosed |
| US-7528132-B2 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds | SCHERING CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| EP-2053406-A2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | caprotec bioanalytics GmbH (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-7504532-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-17 | — | — | US | disclosed |
| US-20090068168-A1 | SUBSTITUTED AMINO ALCOHOLS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2009023967-A1 | PROCESS FOR CONVERTING 9-DIHYDRO-13-ACETYLBACCATIN III INTO DOCETAXEL OR PACLITAXEL | 6570763 CANADA INC. (CA) | 2009-02-26 | — | — | WO | disclosed |
| US-20090023765-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090022806-A1 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof | ORDWAY RESEARCH INSTITUTE, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| US-20090018207-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018132-A1 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| EP-1485707-B1 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | CAPROTEC BIOANALYTICS GMBH (DE) | 2009-01-14 | — | — | EP | disclosed |
| US-7468462-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080312466-A1 | Synthesis and intermediates | OHRLEIN REINHOLD | 2008-12-18 | — | — | US | disclosed |
| US-20080300316-A1 | isotopically enriched phenylephrine derivatives, used for the treatment and/or management of nasal congestion, headaches, asthma, chronic obstructive pulmonary diseases, ischemia, hypotension, and/or any disorder ameliorated by modulating alpha-adrenergic receptors | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7456317-B2 | Deuterated venlafaxine derivatives; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters; for intravenous administration; tablet/capsule form | AUSPEX PHARMACEUTICALS (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080248093-A1 | pH sensitive prodrugs of 2,6-diisopropylphenol | AUSPEX PHARMACEUTICALS, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080242687-A1 | SUBSTITUTED PYRIMIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080234229-A1 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080221069-A1 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-7420078-B2 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof | CIBA SPECIALTY CHEMICALS CORP. (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1951643-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1948646-A2 | SUBSTITUTED PHENYLPIPERIDINES WITH SEROTONINERGIC ACTIVITY AND ENHANCED THERAPEUTIC PROPERTIES | Auspex Pharmaceuticals Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008074858-A1 | INTERMEDIATES AND PROCESS FOR THE PRODUCTION OF 5-SUBSTITUTED TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008068614-A2 | STEREOSELECTIVE SYNTHESIS OF 1-[6-ETHYL-1,2-DIHYDROXY-PROPYL)-PYRIDIN-3-YL]-3-[2-(4-METHYL-PIPERAZIN-1-YL)-BENZYL]-PYRROLIDIN-2-ONE | PFIZER PRODUCTS INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080125587-A1 | Synthesis of triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. | 2008-05-29 | — | — | US | disclosed |
| US-20080125601-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | BASF SE (DE) | 2008-05-29 | — | — | US | disclosed |
| US-20080103189-A1 | PREPARATION AND UTILITY OF SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| EP-1904454-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | Nycomed GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1894911-A1 | VITAMIN D-LIKE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBVIE B.V. (NL) | 2008-01-10 | — | — | US | disclosed |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBVIE B.V. (NL) | 2008-01-10 | — | — | US | disclosed |
| US-7317123-B2 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | TEVA PHARMACEUTICAL INDUSTRIES, LTD (IL) | 2008-01-08 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20070293687-A1 | SEMI-SYNTHETIC ROUTE FOR THE PREPARATION OF PACLITAXEL, DOCETAXEL, AND 10-DEACETYLBACCATIN III FROM 9-DIHYDRO-13-ACETYLBACCATIN III | 6570763 CANADA INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| EP-1680409-A4 | PH SENSITIVE PRODRUGS OF 2,6-DIISOPROPYLPHENOL | AUSPEX PHARMACEUTICALS INC (US) | 2007-12-05 | — | — | EP | disclosed |
| US-7250412-B2 | PH sensitive prodrugs of 2,6-Diisopropylphenol | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070173488-A1 | Pyrazolothiazole Protein Kinase Modulators | SGX PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-7247734-B2 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-07-24 | — | — | US | disclosed |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070142662-A1 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2007-06-21 | — | — | US | disclosed |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007062119-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007058998-A2 | SUBSTITUTED PHENYLPIPERIDINES WITH SEROTONINERGIC ACTIVITY AND ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070112031-A1 | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| EP-1594835-A4 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS INC (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-04-12 | — | — | US | disclosed |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-7199261-B2 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2007-04-03 | — | — | US | disclosed |
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006136552-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1636160-A4 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20060173172-A1 | Method for producing novel spinosyn derivatives | JESCHKE PETER | 2006-08-03 | — | — | US | disclosed |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | HONG BORCHERNG | 2006-08-03 | — | — | US | disclosed |
| EP-1680409-A2 | PH SENSITIVE PRODRUGS OF 2,6-DIISOPROPYLPHENOL | Auspex Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| US-7034130-B2 | Method for producing novel spinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2006-04-25 | — | — | US | disclosed |
| EP-1636160-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | Auspex Pharmaceuticals (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060051879-A9 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | KOSTER HUBERT | 2006-03-09 | — | — | US | disclosed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | disclosed |
| US-20060014800-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| EP-1594835-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | Auspex Pharmaceuticals, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1485707-A4 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS INC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050234050-A1 | Ph sensitive prodrugs of 2,6-diisopropylphenol | AUSPEX PHARMACEUTICALS INC | 2005-10-20 | — | — | US | disclosed |
| EP-1583972-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK Pharmaceuticals, Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | disclosed |
| US-6946556-B1 | Preparation of opioid analgesics by a one-pot process | ACURA PHARMACEUTICALS, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| WO-2005044201-A2 | PH SENSITIVE PRODRUGS OF 2,6-DIISOPROPYLPHENOL | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050042771-A1 | Identifying non-drug targets; use in drug design for improving knowledge of drug-target and drug-non-target interactions, so that drug adverse reactions can be reduced or eliminated in drugs such as troglitazone, rosiglitazone, pioglitazone, methotrexate, atorvastatin, celecoxib, rofecoxib, cerivastatin | CAPROTEC BIOANALYTICS GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| US-20050033086-A1 | Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives | BASF SE (DE) | 2005-02-10 | — | — | US | disclosed |
| WO-2005011573-A2 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050014954-A1 | Pyrrole synthesis | CIBA SPECIALTY CHEMICALS CORP. | 2005-01-20 | — | — | US | disclosed |
| WO-2005000233-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1485707-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK Pharmaceuticals, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040242858-A1 | Method for producing novel spinosyn derivatives | BAYER CROPSCIENCE AG (DE) | 2004-12-02 | — | — | US | disclosed |
| US-20040242916-A1 | Process for preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation | BASF SE (DE) | 2004-12-02 | — | — | US | disclosed |
| US-20040186313-A1 | Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3 5-dihydroxy heptanoic acid derivatives, and intermediates thereof | CIBA SPECIALTY CHEMICALS CORP. | 2004-09-23 | — | — | US | disclosed |
| WO-2004064972-A9 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS INC (US) | 2004-09-16 | — | — | WO | disclosed |
| EP-1451179-A1 | PYRROLE SYNTHESIS | Ciba SC Holding AG (CH) | 2004-09-01 | — | — | EP | disclosed |
| WO-2004064972-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004064745-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| EP-1406860-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES VIA 6-CYANO SYN 3,5-DIHYDROXY HEXANOIC ACID DERIVATIVES | Teva Pharmaceutical Industries Limited (IL) | 2004-04-14 | — | — | EP | disclosed |
| EP-1404639-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES ESPECIALLY 7-AMINO 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, AND INTERMEDIATES THEREOF | Ciba SC Holding AG (CH) | 2004-04-07 | — | — | EP | disclosed |
| EP-1404642-A2 | SYNTHESIS AND INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003092581-A9 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS INC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004009574-A1 | SYNTHESIS OF DISCODERMOLIDE | NOVARTIS AG (CH) | 2004-01-29 | — | — | WO | disclosed |
| US-20030225131-A1 | Thrombin inhibitors | BURGEY CHRISTOPHER S (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003092581-A2 | CAPTURE COMPOUNDS, COLLECTIONS THEREOF AND METHODS FOR ANALYZING THE PROTEOME AND COMPLEX COMPOSITIONS | HK PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| US-20030119021-A1 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2003-06-26 | — | — | US | disclosed |
| WO-2003044011-A1 | PYRROLE SYNTHESIS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003004456-A1 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES VIA 6-CYANO SYN 3,5-DIHYDROXY HEXANOIC ACID DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004455-A2 | PROCESS FOR THE PREPARATION OF 7-AMINO SYN 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, INTERMEDIATES THEREOF AND METHODS FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004450-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF STATIN DERIVATIVES ESPECIALLY 7-AMINO 3,5-DIHYDROXY HEPTANOIC ACID DERIVATIVES, AND INTERMEDIATES THEREOF | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-01-16 | — | — | WO | disclosed |
| US-4020254-A | CATALYTIC POLYMERIZATION | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1977-04-26 | — | — | US | disclosed |
| US-4020254-A | CATALYTIC POLYMERIZATION | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1977-04-26 | — | — | US | disclosed |